What is he best known for?
The fields of study he is best known for:
- Statistics
- Internal medicine
- Diabetes mellitus
Internal medicine, Diabetes mellitus, Type 1 diabetes, Surgery and Clinical trial are his primary areas of study.
His Internal medicine research is multidisciplinary, incorporating elements of Glycated hemoglobin, Type 2 diabetes and Endocrinology.
His Diabetes mellitus research is multidisciplinary, relying on both Gastroenterology, Gerontology and Kidney disease.
His Type 1 diabetes research incorporates themes from Diabetic retinopathy, Retinopathy, Diabetes Therapy, Insulin and Cohort.
His Diabetic retinopathy research is multidisciplinary, incorporating perspectives in Insulin glargine, Insulin pump, Confidence interval, Fundus photography and Diabetes management.
His Surgery study incorporates themes from Epidemiology, Albuminuria, Blood pressure, Stroke and Pharmacotherapy.
His most cited work include:
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. (19535 citations)
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. (14249 citations)
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. (5021 citations)
What are the main themes of his work throughout his whole career to date?
John M. Lachin spends much of his time researching Internal medicine, Diabetes mellitus, Type 1 diabetes, Statistics and Endocrinology.
His Internal medicine research includes elements of Gastroenterology, Type 2 diabetes and Cardiology.
His studies in Type 2 diabetes integrate themes in fields like Metformin and Placebo.
The Diabetes mellitus study combines topics in areas such as Surgery, Epidemiology and Cohort.
His Type 1 diabetes research focuses on subjects like Myocardial infarction, which are linked to Stroke.
His studies deal with areas such as Clinical trial, Econometrics and Restricted randomization as well as Statistics.
He most often published in these fields:
- Internal medicine (50.53%)
- Diabetes mellitus (44.97%)
- Type 1 diabetes (33.33%)
What were the highlights of his more recent work (between 2016-2021)?
- Diabetes mellitus (44.97%)
- Internal medicine (50.53%)
- Type 1 diabetes (33.33%)
In recent papers he was focusing on the following fields of study:
John M. Lachin mainly focuses on Diabetes mellitus, Internal medicine, Type 1 diabetes, Cohort and Proportional hazards model.
Diabetes mellitus is the subject of his research, which falls under Endocrinology.
His work carried out in the field of Internal medicine brings together such families of science as Type 2 diabetes and Cardiology.
His Type 1 diabetes research integrates issues from Diabetic retinopathy, Urology, Epidemiology and Risk factor.
His research in Diabetic retinopathy intersects with topics in Retinopathy, Macular edema, Glycated hemoglobin and Mass screening.
John M. Lachin has researched Cohort in several fields, including Lower risk, Cohort study and Diabetes Therapy.
Between 2016 and 2021, his most popular works were:
- How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (285 citations)
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease (204 citations)
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. (141 citations)
In his most recent research, the most cited papers focused on:
- Statistics
- Internal medicine
- Diabetes mellitus
His primary areas of study are Internal medicine, Diabetes mellitus, Type 1 diabetes, Hazard ratio and Cardiology.
His work is dedicated to discovering how Internal medicine, Empagliflozin are connected with Confidence interval and other disciplines.
His Diabetes mellitus research incorporates elements of Surgery, Disease and Cohort.
His work deals with themes such as Epidemiology, Retinopathy, Proportional hazards model, Glycemic and Risk factor, which intersect with Type 1 diabetes.
As part of the same scientific family, John M. Lachin usually focuses on Retinopathy, concentrating on Ophthalmology and intersecting with Diabetic retinopathy.
His biological study spans a wide range of topics, including Sitagliptin, Type 2 diabetes, Placebo and Renal function.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
